Zinc Supplementation and Inflammation in Older Medical Patients

Starting soon · Not applicable

Conditions studied: Older Medical Patients

In brief

The hypothesis is that a daily supplement of 22 mg of zinc over 12 months can reduce in-flammatory biomarkers in acutely hospitalized older adults aged ≥ 65 years. The aims are to determine, in acutely hospitalized older adults aged ≥ 65 years, if a daily supplement of 22 mg of zinc over 12 months compared to control can decrease inflammato-ry biomarkers, reduce symptoms of self-reported infection, reduce readmission and mortali-ty, increase QoL, increase physical performance, investigate potential adverse events to zinc supplement, and the changes in inflammatory biomarkers. It will also be studied if albumin-corrected zinc in plasma is a more accurate method for assessing zinc status than ordinary plasma zinc.

Key facts

Study ID

NCT07672132

Run by

Herlev Hospital

People needed

220

Starts

2026-06-02

Expected to finish

2028-05-31

Last updated by the study team

2026-06-26

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• above 65 years old included in ZOOM out ( clinical trials no: NCT07367412)
• admittet at the medical emergency department Herlev Hospital

You may not qualify if…

• Patients receiving zinc supplements (>10 mg daily) at time of inclusion
• Patients with terminal illness (life expectancy < 6 months, estimated by Clinical Frailty Scale ≥8)
• Patients receiving parenteral nutrition (partial or complete)
• Patients treated with hemodialysis or peritoneal dialysis
• Patients known with severe dementia
• Patients who do not understand Danish and patients with temporary civil person registration numbers (CPR)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.